Remove Bicuspid/Mitral Remove Hospital Remove Tricuspid
article thumbnail

Columbia Cardiology Launches New Mitral & Tricuspid Center

DAIC

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 111
article thumbnail

Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement

DAIC

milla1cf Thu, 04/25/2024 - 17:21 April 25, 2024 — Atlantic Health System ’s Morristown Medical Center treated the first patient in New Jersey using Edwards Lifesciences EVOQUE tricuspid valve replacement, the first transcatheter therapy to receive U.S. According to National Institutes of Health an estimated 1.6 million people in the U.S.

Tricuspid 111
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100
article thumbnail

Columbia Cardiology Launches New Mitral and Tricuspid Center

DAIC

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

article thumbnail

Early experience with a novel transapical transcatheter aortic valve system in patients with severe aortic stenosis: a prospective, multicenter study

Frontiers in Cardiovascular Medicine

Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4 All patients were pre-TAVR assessed by transthoracic echocardiography and computed tomography of the aortic valve (AV) and relevant left cardiac and vascular anatomy. years old, 55.4%

article thumbnail

Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves

Circulation: Cardiovascular Interventions

BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Poverall=NS) were nonsignificant, and the incidence of overall in-hospital complications was comparable among groups. In the matched population, differences in mortality (30 days: 4.2% 2.44];P=0.035).

article thumbnail

Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

DAIC

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. director of Interventional and Structural Heart Research at Henry Ford Hospital.